Clinical Trial Update: Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure [Phase 2]

View source ↗

Summary

A Phase 2 trial of bosutinib in chronic myeloid leukemia in chronic phase after frontline TKI failure has been terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia Chronic Phase
• Myelogenous Leukemia Bcr-abl1 Positive

Drugs mentioned

• Bosutinib (bosutinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Blasts Under 15 Percent of Bone Marrow Nucleated Cells, Blasts Under 15 Percent of Peripheral Blood White Cells | Phase 2 | Status: TERMINATED | Results posted: 2020-04-22